NCT04987970

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(2) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(2)

Detailed description

An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of CKD-386(2) with co-administration of D013, D326, and D337 in healthy adult volunteers

Conditions

• Hypertension and Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-386(2)	QD, PO
DRUG	D013, D326, D337	QD, PO

Timeline

• Start date: 2021-09-12
• Primary completion: 2021-11-11
• Completion: 2021-11-27
• First posted: 2021-08-03
• Last updated: 2022-02-03

Locations

1 site across 1 country: South Korea